



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 7/08, 7/10, C12Q 1/70	A1	(11) International Publication Number: WO 91/13910 (43) International Publication Date: 19 September 1991 (19.09.91)
(21) International Application Number: PCT/US91/01486 (22) International Filing Date: 8 March 1991 (08.03.91) (30) Priority data: 489,825 9 March 1990 (09.03.90) US (71) Applicant: THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, U.S. DEPARTMENT OF COMMERCE [US/US]; 5285 Port Royal Road, Springfield, VA 22161 (US). (72) Inventors: BERZOFSKY, Jay, A. ; 9321 Corsica Drive, Bethesda, MD 20814 (US). GERMAIN, Ronald, N. ; 10404 Crossing Creek Road, Potomac, MD 20854 (US). PENDLETON, Charles, D. ; 4857 Battery Lane, #410, Bethesda, MD 20814 (US). MOSS, Bernard ; 10301 Dickens Avenue, Bethesda, MD 20814 (US). SCHEARER, Gene, Martin ; 5512 Glenwood Road, Bethesda, MD 20817 (US). HOSMALIN, Ann ; 6, rue Jean-Monnet, F-94270 Kremlin-Bicetre (FR). CLERICI, Mario ; 10201 Grosvenor Place, Apt. 108, Rockville, MD 20852 (US).		(74) Agents: HOLMAN, John, Clarke et al.; Fleit, Jacobson, Cohn, Price, Holman & Stern, The Jenifer Building, 400 Seventh Street, N.W., Washington, DC 20004 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i>
(54) Title: PEPTIDES STIMULATING CYTOTOXIC T CELLS IMMUNE TO HIV RT		
(57) Abstract <p>An epitope in the human immunodeficiency virus-1 (HIV-1) reverse transcriptase that is conserved among HIV strains and that is recognized by both murine and human cytotoxic T cells has been identified. Peptides that are derived from this epitope and that are capable of eliciting cytotoxic T cells that kill cells that express reverse transcriptase are provided. Test kits and methods for identifying HIV-infected individuals using the peptides are also provided. The optimal antigenic side of the HIV-1 reverse transcriptase, which was identified using a murine antigen-specific CD8+ Class I MHC-molecule-restricted cytotoxic T-cell line, includes residues 203-219. This peptide was recognized by cytotoxic lymphocytes from HIV seropositive individuals, but not by cytotoxic lymphocytes from seronegative individuals, and, thus provide a means for diagnosing HIV infection. Test kits and methods for identifying HIV-infected individuals using the peptides are provided. Peptides that include this antigenic site provide a means for producing an immunologic response against a broad range of HIV, and, therefore may be useful for inclusion in an AIDS vaccine. Compositions that contain these peptides and that are formulated for parenteral administration are provided.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

PEPTIDES STIMULATING CYTOTOXIC T CELLS IMMUNE TO HIV RT

T-cell mediated cytotoxicity plays an important role in control of infection by human immunodeficiency virus (HIV). A relatively conserved epitope of HIV-1 reverse transcriptase (RT) recognized by both murine and human cytotoxic T cells has been identified and characterized. The peptides of the invention elicit cytotoxic T cells which kill cells which produce reverse transcriptase of HIV. Since the reverse transcriptase of HIV is conserved to a greater degree than many other HIV proteins, this approach provides a vaccine component that is less affected by mutation of the HIV virus. Hence, the peptides of the invention provide a means of producing an immunologic response against a broad range of strains of the HIV virus.

Abbreviations:

ADCC, antibody-dependent cellular cytotoxicity; CTL, cytotoxic T lymphocyte (s); EBV, Epstein-Barr virus; HIV, human immunodeficiency virus; L-pol, DAP3 fibroblast cell clone transfected with the HIV-1 RT gene; MHC, major histocompatibility complex; NK, natural killer cells; PBMC, peripheral blood mononuclear cells; RT, reverse transcriptase; v-pol, recombinant vaccinia virus containing the HIV-1 RT gene; v-ctrl, negative control recombinant vaccinia virus.

BACKGROUND OF THE INVENTION

Cytotoxic T lymphocytes (CTL) have been found to mediate protection in vivo against certain virus-induced diseases, including some caused by retroviruses (1-3). This defense mechanism might be particularly relevant against HIV, which can spread through cell-cell contact, and thus may not be accessible to antibody neutralization. Indeed, CD8+ cells have been

shown to inhibit growth of HIV or SIV in cells of infected patients or monkeys (4,5). Efforts have thus been directed at studying the CTL response against different proteins of HIV. Human CD3+ 8+ CTL specific
5 for the envelope glycoprotein gp160 have been identified (6-12), and an immunodominant CTL eptiope has been mapped in H-2^d mice to residues 315-329, a highly variable region of the envelope (13). However, immunizing with the whole envelope protein is not an
10 ideal approach for several reasons. First, the majority of the cytotoxic response assayed in vitro with fresh PBMC from HIV seropositive individuals seems to be mediated by non-MHC restricted mechanisms (ADCC or NK) (14). Second, the envelope is highly variable
15 in sequence and CTL clones can distinguish different isolated of HIV (15,16). Third, there is evidence for antibody-dependent enhancement of HIV-1 infection, likely to be mediated by anti-envelope antibodies (17,18). Fourth, immune responses to the HIV envelope
20 have been suggested to contribute to immune deficiency: Uninfected CD4+ T cells which bind gp120 may be killed by ADCC triggered by anti-envelope antibodies (19) or by CD4+ CTL specific for gp120 (20). Anti-gp120 antibodies can also inhibit CD4+ T-cell function like
25 anti-CD4 antibodies by binding to gp120 which binds to CD4 (21). Also, gp160 can elicit autoantibodies that crossreact with human Class II MHC molecules and inhibit T-cell function (22). Finally, gp120 itself may inhibit T-cell function directly (19).
30 In contrast to the envelope glycoprotein, the internal proteins of HIV are more conserved and would be less likely to contribute to these deleterious

effects. Moreover, in other viral models, internal proteins are the predominant targets of the CTL response (23-28). Responses have been found in HIV patients against the products of the gag, pol, nef and vif genes (7,9,12,-29,30). Because of its conservation and importance to viral function, the reverse transcriptase (RT) appears worthy of particular interest in this regard. We describe here our approach of using a murine model to identify evolutionarily conserved CTL determinants in RT and the relevance of this identification to human anti-HIV cytotoxic responses.

LEGENDS TO FIGURES

Fig 1. CTL line Pol α specificity for the N-terminal end of HIV-1 reverse transcriptase. (A) pol gene and the fragment inserted in the recombinant vaccinia virus v-pol and transfected into the fibroblast clone L-pol. The amino acid sequence is deduced from the nucleotide sequence (32). The recombinant viruses v-pol-100 to -27 contained 3'-truncated gene fragments as described in the Methods and in ref. (33). (B) Pol α line specific cytotoxicity on L-pol, L-cells infected with v-pol or with truncated pol gene recombinant vaccinia viruses. \circ , L cells; \bullet , L cells + v-pol; \square , L cells + v-pol-100; \blacksquare , L cells + v-pol-80; \diamond , L cells + v-pol-67; \blacklozenge , L cells + v-pol-58; $+$, L cells + v-pol-27; \triangle , L cells + v-ctrl; \blacktriangle , L-pol.

Fig 2. CTL line Pol α specificity for peptide HP138. L-cells were incubated overnight with peptides at a concentration of 20 μ M and with ^{51}Cr as described in the Methods, then used as targets with different numbers of Pol α effector cells. The sequences of the

peptides are following: HP 134: (175-189), HP 135: (185-199), HP 136: (193-207, HP 137: (199-213), HP 138: (205-219), HP 139: (215-229), HP 140: (299-244), HP 141: (238-252), HP 142: (243-257), HP 144: (265-279), HP 145: (275-289), HP 146: (283-297), HP 147: (288-302), HP 148: (300-314), HP 149: (311-325), HP 150: (315-329), HP 151: (324-339), HP 152: (329-343), HP 154: (355-369), HP 143 (255-269) and HP 153: (344-359) could not be tested because they were insoluble. + , L-pol; ○ , L cells; ● , L cells + HP 134 + HP 146; □ , L cells + HP 135 + HP 147; ■ , L cells + HP 136; △ , L cells + HP 137 + HP 148; × , L cells + HP 138; ▲ , L cells + HP 139 + HP 149; ◻ , L cells + HP 140 + HP 150; ▣ , L cells + HP 141 + HP 151; △ , L cells + HP 142 + HP 152; ▲ , L cells + HP 144 + HP 154; ◆ , L cells + HP 145 + HP 155.

Fig 3. Localization of the CTL epitope in the pol 199-223 area. ○ , 205-219; ● , 203-219; □ , 207-223; ■ , 205-223; △ , 199-223; ▲ , 203-218. 205-219, which is the sequence of HP138, has been resynthesized along with its analogs.

Fig 4. Recognition of the immunodominant murine epitope of HIV-1 RT by peripheral blood cells from two HIV infected patients and two seronegative controls. EBV-transformed B cells derived from HIV infected donors or HIV controls were used as targets as described in the Methods. Aliquots of each individual's target cells were incubated overnight with a concentration of 10 μ M of peptides 203-219 (□), 205-219 (○) or 255-269 (△) (HP 145, a control peptide without any activity in the murine tests as shown in Fig 2, and not predicted to be a T-cell epitope by the

AMPHI algorithm (43)). Other aliquots of target cells were infected with v-pol (●) or with v-ctrl (■). The targets were then assayed with autologous PBMC as effectors in 6hr ^{51}Cr release assay. The error bars show the standard error of the mean of the triplicates (SEM). Upper panel, targets pre-incubated with peptides. Lower panel, targets infected with viruses. ▲, targets pre-incubated in medium only.

Fig 5. Lysis of target cells incubated with 205-219 by autologous PBMC. Comparison of all the seropositive patients (HIV^+) and the seronegative controls (HIV^-). Each point represents the % specific ^{51}Cr release of peptide-incubated targets after a 6 hr assay in presence of autologous PBMC at the maximal E:T ratio tested (80 or 40:1). For each HIV^+ donor, control target cells either with no peptide or with control vaccinia virus were not lysed. Two patients who had % specific releases at 11 and 12%, respectively, were not included in this figure because no adequate negative control was available.

SUMMARY OF THE INVENTION

T-cell mediated cytotoxicity plays an important role in control of infection by the human immunodeficiency virus (HIV). A relatively conserved epitope in the HIV-1 reverse transcriptase recognized by both murine and human cytotoxic T cells has been discovered. This epitope was identified using a murine antigen-specific CD8^+ Class I MHC-molecule-restricted cytotoxic T-cell (CTL) line, a transfected fibroblast cell line expressing the HIV-1 pol gene, recombinant vaccinia viruses containing different truncated versions of the pol gene, and overlapping synthetic

peptides. The optimal antigenic site was identified as residues 203-219 by synthesizing extended or truncated peptide analogs of the antigenic fragment. The optimal peptide was then tested for sensitization of autologous
5 EBV-transformed B cell targets for killing by fresh human peripheral blood mononuclear cells. The peptide was recognized by CTL from several HIV seropositive patients but not from any seronegative donor. Hence, this peptide is a good immunogen for inclusion in an
10 AIDS vaccine. The data demonstrates that the same CTL epitope can be seen by murine and human CD8+ CTL, as previously demonstrated for epitopes recognized by CD4+ helper T cells, and indicates the utility of screening for immunodominant CTL epitopes in mice prior to
15 carrying out studies in humans.

Although consistent with an amphipathic 3_{10} helix, these peptides are not strongly predicted by any of the known predictive methods. Hence, the peptides would not have been selected by one of ordinary skill in the
20 art as a likely candidate T cell epitope peptides.

MATERIALS AND METHODS

Mice. C3H/HeJ (H-2k) mice were obtained from the Jackson Laboratories (Bar Harbor, ME, USA).

Recombinant vaccinia viruses.

25 V-pol (vCF-21, Fig. 1) (31) and v-pol-100 are recombinant vaccinia viruses containing the RT gene of HTLVIII subclone HXB.2 except for the last 22 residues (pol gene deduced amino acid sequence 168-706 for the insert, 168-728 for RT) (32). The truncated pol gene-
30 recombinant vaccinia viruses (vCF 32, 33, 34, 35, and 37) (33) have been re-named in this application v-pol-100, -80, -67, -58, and -27, respectively, to indicate

the proportional length of their inserts as a % of the v-pol-100 insert length (Fig. 1). These inserts all initiate at the 5' end of the original insert, corresponding to residue 168 of the amino acid sequence and to the N-terminal end of the precessed protein. v-ctrl (vSC-8) (34) contains the E. coli lac-Z gene as a control.

Transfectants.

The transfectant L-pol was prepared using the pcEXV-3 vector containing the same RT-encoding insert as v-pol. pcEXV-3-pol was cotransfected with pSV2neo into DAP-3 L cells using the CaPO4 method (35) and clones were isolated after selection in G418. A single clone (RGT 1.10.7) having a high level of pol transcripts in RNA dot-blot analysis was selected for use in these experiments. The control L cells (L28) were prepared with pSV2 neo alone.

Generation of a murine CTL line.

The line Pol a was obtained from v-pol immunized (107 PFU IV) C3H/HeJ female mouse spleen cells restimulated in vitro with mitomycin-C treated L-pol transfectants as in (13) (5×10^6 spleen cells, 5×10^5 L-pol cells/well in 24-well plates), but in presence of supplemented medium, i.e. complete T-cell medium containing 10% Concanavalin A stimulated rat spleen cell medium (T-cell Monoclonal, Collaborative Research Inc., Bedford, MA). The line has been maintained now for more than a year by weekly restimulations (0.3×10^6 line cells, 10^6 L-pol cells) and bi-weekly feeding with supplemented medium. It has been used for assays not earlier than 3 days after a T-cell Monoclonal addition.

CTL assay.

The murine CTL assays were performed as in reference (13), with the following differences: 10^6 L-cells were infected with recombinant vaccinia viruses at a multiplicity of infection of 50 for 1 hour, then washed and incubated overnight with ^{51}Cr ; in other experiments, L-cells were incubated overnight with peptides and with ^{51}Cr (0.3×10^6 cells, 0.05 mCi (1.85 MBQ)/well in 24-well plates). The target cells were then washed four times before use in the 6-hour assay (5000 target cells/well in 96 round-bottom well plates). In the human assays, lines derived from peripheral blood mononuclear cells (PBMC) of donors by Epstein-Barr virus (EBV) transformation were either pulsed overnight with 10¹ or infected with recombinant vaccinia virus (multiplicity of infection=100) for 1 hour, then washed. In both cases they were labeled overnight with 0.3mCi (11.1 MBQ) and used as targets (5000/well) the following day in a 6-hr ^{51}Cr release assay with unstimulated cryopreserved PBMC from the same donor as effectors. The percentage specific release was calculated as $100 \times (\text{experimental } ^{51}\text{Cr release} - \text{spontaneous release}) / (\text{maximum release} - \text{spontaneous release})$.

Peptide synthesis.

A series of 15-residue peptides covering the fraction of RT sequence (HXB.2 subclone of HTLVIII/B) (32) that was expressed by the virus v-pol-27 were synthesized and purified as described previously (13,36). Their molar concentration was determined by HPLC or by spectrophotometry. A series of analogs of peptide HP 138 have been synthesized on an ABI

automated synthesizer, cleaved by low HF procedure, desalted either by P4-biogel or by reverse-phase (C18 Sep-Pak, Waters) chromatography, and when necessary purified to a single HPLC peak (C18 column, Waters).

- 5 Amino acid analysis (performed by O. Bates and coll., University of California, Irvine) confirmed the expected sequences.

Patient source and clinical evaluation.

- HIV+ patients were obtained from Wilford Hall
10 United States Air Force Medical Center, Lackland Air Force Base, TX. Individuals were diagnosed as being HIV infected if anti-HIV antibodies were demonstrated on two specimens tested by the HIV enzyme immunoassay (Abbott Laboratories, Irving, TX) and confirmed by
15 Western blot analysis (Roche Biomedical Laboratories, Burlington, NC). Patients were classified according to the Walter Reed Staging System (37). Lymphocyte counts and T cell subsets were determined using laser-based flow cytometry (Coulter Epics Profile, Coulter
20 Electronics, Inc., Hialeah, FL) and OKT4A (anti-CD4) and OKT8 (anti-CD8) monoclonal antibodies (Orthodiagnosics Systems, Raritan, NJ).

EXAMPLE 1

- Generation of murine CTL line (Pol a) specific for the
25 N-terminal end of HIV-1 reverse transcriptase: The CTL line Pol a was derived from spleen cells of C3H/HeJ mice immunized with the recombinant vaccinia virus v-pol and restimulated in vitro with an H-2^k fibroblast line (L-pol) transfected with the same HIV-1 pol gene
30 insert. This CTL line (Fig. 1) lysed specifically L-pol as well as untransfected H-2^k fibroblasts (L-cells) infected by v-pol, but not L-cells infected by the

control vaccinia virus v-ctrl. Therefore, the HIV-1 pol gene fragment expressed at least one CTL epitope recognized on H-2^k fibroblasts.

To localize the epitope(s), L cells were first
5 infected with recombinant vaccinia viruses expressing truncated versions of the pol gene (Fig. 1) and these cells were used as targets in a cytotoxicity assay with the Pol a CTL line. The targets infected with viruses containing from 100% to as little as 27% of the N-
10 terminal part of the original insert were all lysed to a comparable extent (Fig. 1). This experiment indicated that an immunodominant epitope was present in the portion of the protein encoded by the shortest pol insert (27% of the original insert, i.e. residues 168
15 to 316). This area corresponds to the N-terminal end of RT. Other epitopes may have been present in the remainder of the sequence, but this portion by itself was able to induce maximal lysis.

EXAMPLE 2

20 Identification of the immunodominant epitope recognized by the line Pol a: To identify the epitope(s) contained in this area, we used 21 overlapping 15-amino acid peptides designated HP134 to HP154 covering residues 168 to 316. L-cells were incubated overnight
25 with ⁵¹Cr together with peptides (20 μM, and tested for lysis by Pol a. To reduce the number of different targets to be tested, we analyzed mixtures of two peptides at a time, but avoided mixing overlapping peptides that might have a higher risk of inhibiting
30 each other by sharing the same MHC binding site. Because preliminary experiments had suggested that peptide HP138 was responsible for targeting the

cytotoxic activity, HP138 was tested individually and found to sensitize targets (Fig 2). However, none of the other peptides was able to sensitize targets (Fig 2), including HP137 and 139 [that overlap HP138 by 9 and 5 residues, respectively] even when tested individually (data not shown). HP138 (CTEMEKEGKISKIGP) corresponds to residues 205-219 of the HTLV/IIIB strain sequence (32). The peptide is not toxic by itself as determined by spontaneous lysis and cell recovery in the presence of peptide alone (data not shown). The line Pol a was Class I MHC-restricted because it killed HP 138-pulsed, Class II MHC molecule-negative H-2^k L-cell fibroblasts, but not 3T3 fibroblasts (H-2^d) or EL4 thymoma cells (H-2^b). It was demonstrated to be CD4-CD8+ by treatment with anti-CD8 or anti-CD4 monoclonal antibodies and complement (data not shown).

DEFINITION OF OPTIMAL EPITOPES

Because HP138 sensitized targets best at high concentrations (20 μ M) a series of peptide analogs were synthesized and purified in the area of HP138 to determine whether activity could be improved by extending or shortening the peptide by a few residues. The addition of two amino acids (Figure 3) on the N-terminal side of the sequence (peptide 203-219) induced both a higher maximal specific release (more than 60% vs 40%) and a 30-fold lower concentration needed to obtain half-maximal activity (about 0.3 μ M vs 10 μ M). In contrast, removal of residues 205 and 206 at the N-terminus abrogated all activity (peptide 207-223 compare to 205-223). This result suggests that a critical determinant is at the N-terminus of HP 138. The addition of amino acids on the C-terminal end of

205-219 (peptide 205-223) also enhanced the activity (plateau at 60%, half-maximal lysis at about 1 μ M), but was not able to restore the loss of activity when residues 205 and 206 were missing in peptide 207-223.

- 5 Peptide 199-223 contained both the two residues 203 and 204 and the elongation of the C terminus that enhanced the activity in 205-223, but suprisingly its activity was not beter than that of 205-223 (same maximal activity, half-maximal lysis at about 2 μ M), as if the
10 sequence 199-202 was partly inhibiting the recognition. Finally, the removal of the proline residue 219 did not modify the maximal activity of peptide 203-219 but increased slightly the concentration necessary for half-maximal lysis (20 μ M, peptide 203-218).

15 **RECOGNITION OF THE EPITOPE BY HUMAN CYTOTOXIC CELLS**

- In order to determine whether the epitope for CD8+ class I MHC-restricted CTL identified in the mouse model would be recognized by cells from HIV_infected humans, PBMC from 2 HIV seropositive and 2 seronegative
20 individual were tested, without restimulation in vitro, for the lysis of autologous EBV-transformed cells incubated overnight with peptides 205-219 (Fig. 4, upper panel). The PBMC from both patients were able to kill specifically targets preincubated with the two
25 peptides, but not targets preincubated with a control peptide or with medium only. Conversely, the PBMC from both seronegative donors failed to kill the targets incubated with either peptide, but did show some killing on autologous target cells infected with the
30 control vaccinia virus (Fig. 4, lower panel). The latter cytolytic activity probably is a memory response resulting from a prior smallpox vaccination. Two

patients, but not the healthy controls, also showed a high cytotoxic activity against the targets infected with the pol-recombinant vaccinia virus (Fig. 4, lower panel). For one of these two donors (patient 2) the
5 phenotype of the effector cells was tested. The activity was blocked by anti-CD3 and anti-CD8, but not by anti-CD4 monoclonal antibodies and complement, and was genetically restricted (data not shown). Thus, these conventional antigen specific MHC restricted CD8+
10 CTL. The cells from 12 HIV seropositive patients and 5 controls have been tested (Fig. 5). The level of killing after incubation of the target cells with HP138, peptide 203-219 or 205-219 was higher than 10% in 5 of the 12 patients, whereas it ranged from <0 to
15 3.2% in the seronegative donors.

The epitope 203-219 is in a region highly conserved in evolution among reverse transcriptase genes of other viruses. For this reason it is likely to be essential for RT activity and may, therefore, not tolerate
20 substitutions required for escape from the immune system. When the residues 203-219 and 205-219 were compared, it was shown that the two residues (203 and 204) enhanced dramatically the activity of the original peptides, whereas the analog missing residues 205 and
25 206 had no activity at all. Thus, the sequence 203-206 seems essential for optimal activity of the peptide. It is also possible to enhance the activity by elongating the original peptide on the C-terminal side. Interestingly, a longer analog encompassing both the N-
30 and C- terminal extensions did not reach the same level of activity as the optimal epitope 203-219. Additional residues contained on the N-terminal side may include a

hindering structure similar to those found in Class-II restricted epitopes.

The peptides of the invention should preferably contain at least 15 amino acids, though it may contain
5 as many as 40 amino acids. However, at least 12 amino acids should be show homology to the most preferred 17 amino acid sequence. In any case, the Cys-Thr peptides should be conserved. The cysteine amide of the preferred peptide Glu-Ile-Cys-Thr-Glu-Met-Glu-Lys-Glu-
10 Gly-Lys-Ile-Ser-Lys-Ile-Gly-Pro is particularly preferred.

The peptides of the invention may be given in the usual carriers containing adjuvants such as alum and Freund's adjuvant. A preferred composition would
15 contain the peptides in an emulsion, which would protect the peptide and which provide for slow release delivery.

The preparations of the invention can be given parenterally. Preferred means of administration are
20 subcutaneous, intramuscular or intravenous routes. A preferred method of administrations is by intravenous route. Interleukin 2 or other response potentiators may be given simultaneously either as a component of the composition containing the peptide or as a separate
25 injection. Such potentiators include but are not limited to interleukin 4, muramyl-dipeptide, adjuvants such alum or Freund's adjuvant or mycobacterium or mycobacterial products such as BCG. The peptides given as immune therapy may be given intravenously initially
30 with repeat injections at 1 to 3 day intervals thereafter until desired level of T cell activity is evidenced. The physician may then monitor killer T

cell activity and repeat the protocol when decrease in killer T cell activity is observed.

The peptides of the invention may or may not raise antibodies to the HIV virus. Since the killer T-cells
5 affect the infectivity of the HIV virus present in any cell in the body, it may be possible to treat individuals that have been exposed to the HIV virus before sufficient exposure to viral protein to raise antibodies. Hence, the therapy may prevent such
10 individuals from becoming sero-positive.

Since T-cell response is often raised before any antibodies are found in the blood in measurable amounts, the peptides of the invention can be used to test for latent infection by exposing the donor cells
15 to the peptides and testing for T cell response. Hence, the peptides are useful as part of a diagnostic kit to screen seronegative blood donors or other individuals.

REFERENCES

1. Pasternack, M.S. (1988) *Adv. Intern. Med.* 33, 17-44.
2. Earl, P.L., Moss, B., Morrison, R.P., Wehrly, K.,
Nishio, J. & Chesebro, B. (1986) *Science* 234, 728.
- 5 3. Plata, F., Langlade-Demoyen, P., Abastado, J.P.,
Berbar, T. & Kourilsky, P. (1987) *Cell* 48, 231-240.
4. Walker, C.M., Moody, D.J., Stites, D.P. & Levy, J.A.
(1986) *Science* 234, 1563-1566.
5. Tsubota, H., Lord, C.I., Watkins, D.I., Morimoto, C.
10 & Letvin, N.L. (1989) *J. Exp. Med.* 169, 1421-1434.
6. Walker, B.D., Chakrabarti, S., Moss, B., Paradis,
T.J., Flynn, T., Durno, A.G., Blumberg, R.S.,
Kaplan, J.C., Hirsch, M.S. & Schooley, R.T. (1987)
Nature 328, 345-351.
- 15 7. Walker, B.D., Flexner, C., Paradis, T.J., Fuller,
T.C., Hirsch, M.S., Schooley, R.T. & Moss, B. (1988)
Science 240, 64-66.
8. Langlade-Demoyen, P., Michel, F., Hoffenbach, A.,
Vilmer, E., Dadaglio, G., Garicia-Pons, F., Mayaud,
20 C., Autran, B., Wain-Hobson, S. & Plata, F. (1988)
J. Immunol. 141, 1949-1957.
9. Riviere, Y., Tanneau-Salvadori, F., Regnault, A.,
Lopez, O., Sansonetti, P., Guy, B., Kieny, M.P.,
Fournel, J.J. & Montagnier, L. (1989) *Journal of*
25 *Virology* 63, 2270-2277.
10. Sethi, K.K., Näher, H. & Stroehmann, I. (1988)
Nature 335, 178-181.
11. Shepp, D.H., Daguiard, F., Mann, D. & Quinnan,
G.V. (1988) *AIDS* 2, 113-117.
- 30 12. Koup, R.A., Sullivan, J.L., Levine, P.H., Brettler,
D., Mahr., A., Mazzara, G., McKenzie, S. &
Panicali, D. (1989) *Blood* 73, 1909-1914.

13. Takahashi, H., Cohen, J., Hosmalin, A., Cease, K.B., Houghten, R., Cornette, J., Delisi, C., Moss, B., Germain, R.N. & Berzofsky, J.A. (1988) Proc. Natl. Acad. Sci. USA 85, 3105-3109.
- 5 14. Rosenberg, Z.F. & Fauci, A.S. (1989) Adv. Immunol. 47, 377-431.
15. Takahashi, H., Houghten, R., Putney, S.D., Margulies, D.H., Moss, B., Germain, R.N. & Berzofsky, J.A. (1989) J. Exp. Med., in press.
- 10 16. Takahashi, H., Merli, S., Putney, S.D., Houghten, R., Moss, B., Germain, R.N. & Berzofsky, J.A. (1989) Science 246, 118-121.
17. Robinson, W.E.Jr., Montefiori, D.C., Mitchell, W.M., Prince, A.M., Alter, H.J., Dreesman, G.R. & Eichberg, J.W. (1989) Proc. Natl. Acad. Sci. U.S.A. 86, 4710-4714.
- 15 18. Takeda, A., Tuazon, C.U. & Ennis, F.A. (1988) Science 242, 580-583.
19. Weinhold, K.J., Lyster, H.K., Stanley, S.D., Austin, A.A., Matthews, T.J. & Bolognesi, D.P. (1989) J. Immunol 142, 3091-3097.
- 20 20. Siliciano, R.F., Trebor, L., Knall, C., Karr, R.W., Berman, P., Gregory, T. & Reinherz, E.L. (1988) Cell 54, 561-575.
- 25 21. Mittler, R.S. & Hoffmann, M.K. (1989) Science 245, 1380-1382.
22. Golding, H. Shearer, G.M., Hillman, K., Lucas, P., Manischewitz, J., Zajac, R.A., Clerici, M., Gress, R.E., Boswell, N.R. & Golding, B. (1989) J. Clin. Invest. 83, 1430-1435.
- 30 23. Townsend, A.R.M., Rothbard, J., Gotch, F.M., Bahadur, G., Wraith, D. & McMichael, A.J. (1986)

Cell 44, 959-968.

24. Yewdell, J.W., Bennink, J.R., Smith, G.L. & Moss, B. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 1785-1789.
- 5 25. Kees, U. & Krammer, P.H. (1984) J. Exp. Med. 159, 365-377.
26. Yewdell, J.W., Bennink, J.R., Mackett, M., Lefrancois, L., Lyles, D.S. & Moss, B. (1986) J. Exp. Med. 163, 1529-1538.
- 10 27. Bangham, C.R.M., Openshaw, P.J.M., Ball, L.A., King, A.M.Q., Wertz, G.W. & Askonas, B.A. (1986) J. Immunol. 137, 3973-3977.
28. Puddington, L., Bevan, M.J., Rose, J.K. & Lefrancois, L. (1986) Journal of Virology 60, 708-15 717.
29. Claverie, J.-M., Kourilsky, P., Langlade-Demoyen, P., Chalufour-Prochnicka, A., Dadaglio, G., Tekaiia, F., Plata, F. & Bougueleret, L. (1988) Eur. J. Immunol. 18, 1547-1553.
- 20 30. Nixon, D.F., Townsend, A.R.M., Elvin, J.G., Rizza, C.R., Gallwey, J. & McMichael, A.J. (1988) Nature 336, 484-487.
31. Flexner, C., Broyles, S.S., Earl, P., Chakrabarti, S. & Moss, B. (1988) Virology 166, 339-349.
- 25 32. Ratner, L., Haseltine, W., Patarca, R., Livak, K.J., Starcich, B., Josephs, S.F., Doran, E.R., Rafalski, J.A., Whitehorn, E.A., Baumeister, K., Ivanoff, L., Petteway, S.R., Jr., Pearson, M.L., Lautenberger, J.A., Papas, T.S., Ghrayeb, J., 30 Chang, N.T., Gallo, R.C. & Wong-Staal, F. (1985) Nature 313, 277-277.

33. Walker, B.D., Flexner, C., Birch-Limberger, K.,
Fisher, L., Paradis, T.J., Aldovini, A., Young, R.,
Moss, B. & Schooley, R.T. (1989) Proc. Natl. Acad.
Sci. U.S.A., in press.
- 5 34. Chakrabarti, S., Robert-Guroff, M., Wong-Staal, F.,
Gallo, R.C. & Moss, B. (1986) Nature 320, 535-537.
35. Margulies, D.H., Evans, G.A., Ozato, K., Camerini-
Otero, R.D., Tanaka, K., Appella, E. & Seidman,
J.G. 91983) J. Immunol. 130, 463.
- 10 36. Houghten, R.A. (1985) Proc. Natl. Acad. Sci, USA.
82, 5131-5135.
37. Redfield, R.R., Wright, D.C. & Tramont, E.C. (1986)
New Engl. J. Med. 314, 131-132.
38. Myers, G., Josephs, S.F., Berzofsky, J.A., Rabson,
15 A.B., Smith, T.F. & Wong-Staal, F. 91989) Human
Retroviruses and AIDS 1989 (Los Alamos National
Laboratory, New Mexico).
39. Kumar, S., Miller, L.H., Quakyi, I.A., Keister,
D.B., Houghten, R.A., Maly, W.L., Moss, B.,
20 Berzofsky, J.A. & Good, M.I. (1988) Nature 334,
258-260.
40. Brett, S.J., Cease, K.B. & Berzofsky, J.A. (1988)
J. Exp. Med. 168, 357-373.
41. Bodmer, H.C., Gotch, F.M. & McMichael, A.J. (1989)
25 Nature 337, 653-655.
42. Vacchio, M.S., Berzofsky, J.A. Krzych, U., Smith,
J.A., Hodes, R.J. & Finnegan, A. (1989) J. Immunol.
143, 2814-2819.
43. Margalit, H., Spouge, J.L., Cornette, J.L., Cease,
30 K., Delisi, C. & Berzofsky, J.A. (1987) J. Immunol.
138, 2213-2229.

44. Good, M.F., Maloy, W.L., Lunde, M.N., Margalit, H., Cornette, J.L., Smith, G.L., Moss, B., Miller, L.H. & Berzofsky, J.A. (1987) *Science* 235, 1059-1062.
45. Good, M.F., Pombo, D., Quakyi, I.A., Riley, E.M.
5 Houghten, R.A., Menon, A., Alling, D.W., Berzofsky, J.A. & Miller, L.H. (1988) *Proc. Natl. Acad. Sci. USA* 85, 1199-1203.
46. Dontfraid, F., Cochran, M.A., Pombo, D., Knell, J.D., Quakyi, I., Kumar, S., Houghten, R.A.
10 Berzofsky, J.A., Miller, L.H. & Good, M.F. (1988) *Mol. Biol. Med.* 5, 185-196.
47. Hale, P.M. Cease, K.B., Houghten R.A., Ouyang, C., Putney, S., Javaherian, K., Margalit, H., Cornette, J.L., Spouge, J.L., Delisi, C. & Berzofsky, J.A.
15 (1989) *Internat. Immunol.* 1, 409-415.
48. Berzofsky, J.A., Bensussan, A., Cease, K.B., Bourge, J.F., Cheynier, R., Lurhuma, Z., Salaün, J.-J., Gallo, R.C., Shearer, G.M. & Zagury, D. (1988) *Nature* 334, 706-708.
- 20 49. Clerici, M., Stocks, N.I., Zajac, R.A., Boswell, R.N., Bernstein, D.C., Mann, D.L., Shearer, G.M. & Berzofsky, J.A. (1989) *Nature* 339, 383-385.
50. Lamb, J.R., Eckels, D.D., Lake, P., Woody, J.N. & Green, N. (1982) *Nature* 300, 66-69.
- 25 51. Hurwitz, J.L., Heber-Katz, E., Hackett, C.J. & Gerhard, W.J. (1984) *J. Immunol.* 133, 3371-3377.
52. Achour, A., Fossati, I., Margaritte, C., Berzofsky, J.A., Gallo, R.C. & Zagury, D. (1989) *Vth International Conference on AIDS, Montreal*
30 546. (Abstract)
53. Kronenberg, M., Siu, G., Hood, L.E. & Shastri, N. (1986) *Annu. Rev. Immunol.* 4, 529-591.

54. Klein, J. & Figueroa, F. (1986) CRC Crit. Rev.
Immunol. 6, 295-386.
55. Clerici, M., Stocks, N.I., Zajac, R.A., Boswell,
R.N., Lucey, D.R., Via, C.S. & Shearer, G.M. (1989)
5 J. Clin. Invest., in press.

CLAIMS

1. A peptide of 15 to 40 amino acids which may be glycosylated or unglycosylated, or their amides which have at least 12 amino acids homologous to the peptide
5 of the amino acid sequence Glu-Ile-Cys-Thr-Glu-Met-Glu-Lys-Glu-Gly-Lys-Ile-Ser-Lys-Ile-Gly-Pro
with the proviso that the Cys-Thr amino acids must be homologous, including peptides which may be protected.
2. A peptide of claim 1 containing the sequence:
10 Glu-Ile-Cys-Thr-Glu-Met-Glu-Lys-Glu-Gly-Lys-Ile-Ser-Lys-Ile-Gly-Pro.
3. A peptide of claim 1 wherein the amino acid sequence is
15 Glu-Ile-Cys-Thr-Glu-Met-Glu-Lys-Glu-Gly-Lys-Ile-Ser-Lys-Ile-Gly-Pro.
4. A peptide of claim 1 containing the sequence
Cys-Thr-Glu-Met-Glu-Lys-Glu-Gly-Lys-Ile-Ser-Lys-Ile-Gly-Pro.
5. A composition of matter comprising, as an active
20 ingredient, at least one peptide of claim 1 in a carrier.
6. A composition of claim 5 wherein the peptide contains the sequence
25 Glu-Ile-Cys-Thr-Glu-Met-Glu-Lys-Glu-Gly-Lys-Ile-Ser-Lys-Ile-Gly-Pro.
7. A composition of claim 5 wherein the peptide contains the sequence
Cys-Thr-Glu-Met-Glu-Lys-Glu-Gly-Lys-Ile-Ser-Lys-Ile-Gly-Pro.
- 30 8. A composition of claim 5 which contains an immune potentiator.

9. A composition of claim 8 which contains an adjuvant.
10. A composition of claim 8 wherein the adjuvant is alum.
- 5 11. A composition of claim 8 having as a potentiator interleukin 2 or interleukin 4.
12. A method of identifying patients infected with HIV comprising the steps of:
- 10 (1) Obtaining peripheral blood mononuclear cells from an individual;
- (2) Incubating autologous target cells with a peptide of claim 1 and a marker;
- (3) Adding the cells of step (1) to the incubated material from step (2) and incubating; and
- 15 (4) Measuring the amount of marker released to determine T cell response.
13. A method of claim 12 where in the marker is ^{51}Cr .
14. A method of claim 12 wherein the autologous target cells are EBV-transformed B-lymphoblastoid cells.




FIG. I

2/5




FIG. 2




FIG. 3




FIG. 4

5/5





FIG. 5

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/01486

I. CLASSIFICATION OF SUBJECT MATTER In several classification systems apply indication 1-3 According to the International Patent Classification (IPC), the subject matter is classified in the following classes:		
US Cl.: 530/326,325,324; 514/12,13,14; 435/5 IPC(5): C07K 7/08, 7/10; C12Q 1/70		
II. FIELDS SEARCHED		
Minimum Documentation Searched *		
Classification System U.S.CL.	Classification Symbols 530/326,325,324; 514/14,13,12; 435/5	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
Sequence search in CAS, PIR, and Swiss-Prot Sequence Databases		
III. DOCUMENTS CONSIDERED TO BE RELEVANT *		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages 12	Relevant to Claim No. 3
A	Proceedings National Academy of Sciences. Volume 87. issued March 1990. A. Hosmalin. "An epitope in human immunodeficiency virus I reverse transcriptase recognized by both mouse and human cytotoxic T Lymphocytes". pages 2344-2348. See abstract.	1-14
A	Proceedings National Academy of Sciences. volume 82. issued October 1985. C DeLisi. "T-cell antigenic sites tend to be amphipathic structures". pages 7048-7052. see abstract.	1-14
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>* Special categories of cited documents: 10</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"S" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 14 June 1991 International Searching Authority ISA/US	Date of Mailing of this International Search Report <div style="font-size: 1.2em; font-weight: bold;">16 JUL 1991</div> Signature of Authorized Officer  Susan M. Perkins	